163217-70-7

Basic information

• Product Name: P-HYDROXY ATORVASTATIN LACTONE
• Synonyms: P-HYDROXY ATORVASTATIN LACTONE;5-(4-Fluorophenyl)-N-(4-hydroxyphenyl)-2-(1-Methylethyl)-4-phenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxaMide;5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-N-(4-hydroxyphenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxaMide;4-Hydroxy Atorvastatin Lactone (EP);Atorvastatin 4-Hydroxy Lactone;5-(4-Fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)-ethyl)-N-(4-hydroxyp
• CAS NO: 163217-70-7
• Molecular Formula: C33H33FN2O5
• Molecular Weight: 556.62
• Product Categories: Various Metabolites and Impurities;Metabolites
• Mol File: 163217-70-7.mol
• Article Data: 2

Chemical Properties

• Melting Point: 103-106°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• CAS DataBase Reference: P-HYDROXY ATORVASTATIN LACTONE(CAS DataBase Reference)
• NIST Chemistry Reference: P-HYDROXY ATORVASTATIN LACTONE(163217-70-7)
• EPA Substance Registry System: P-HYDROXY ATORVASTATIN LACTONE(163217-70-7)

Safety Data

• Hazardous Substances Data: 163217-70-7(Hazardous Substances Data)

Usage

Description

P-HYDROXY ATORVASTATIN LACTONE is a metabolite of Atorvastatin, which is a selective, competitive HMG-CoA reductase inhibitor. It is a pale-yellow to tan solid and plays a significant role in the treatment of hypercholesterolemia.

Uses

Used in Pharmaceutical Industry:
P-HYDROXY ATORVASTATIN LACTONE is used as a therapeutic agent for the treatment of hypercholesterolemia. It functions by lowering elevated levels of LDL-cholesterol and triglycerides in patients, thus helping to manage and reduce the risk of cardiovascular diseases.
Used in Research and Development:
As a metabolite of Atorvastatin, P-HYDROXY ATORVASTATIN LACTONE is also used in research and development for further understanding the mechanisms of action, pharmacokinetics, and potential applications in the treatment of other related conditions. This can lead to the development of new drugs or improved drug formulations with enhanced efficacy and safety profiles.

Upstream product

• 214217-88-6 p-Hydroxyatorvastatin 
• 6373-46-2 p-benzyloxyaniline 
• 265989-30-8 N-(4-(benzyloxy)phenyl)-4-methyl-3-oxopentanamide 
• 163217-66-1 2-benzylidene-N-(4-(benzyloxy)phenyl)-4-methyl-3-oxopentanamide 
• 163217-67-2 N-(4-(benzyloxy)phenyl)-2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxopentanamide 
• 265989-36-4 tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-hydroxyphenyl)carbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 163217-68-3 tert-butyl 2-((4R,6R)-6-(2-(3-((4-(benzyloxy)phenyl)carbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 103-50-4 dibenzyl ether 

Relevant articles and documents

Synthesis of deuterium-labeled atorvastatin and its metabolites for use as internal standards in a LC/MS/MS method developed for quantitation of the drug and its metabolites in human serum

D5-labeled isotopomers of atorvastatin, atorvastatin lactone and its hydroxy metabolites were synthesized as internal standards for use in a LC/MS/MS method developed for the simultaneous quantitative determination of atorvastatin and its hydroxy metabolites in human serum. d5-Atorvastatin and d5-atorvastatin lactone were prepared from d5-aniline whereas their corresponding hydroxy metabolites were synthesized using d5-benzaldehyde.